Lymph node metastasis of papillary thyroid carcinoma in the context of Hashimoto's thyroiditis

被引:23
作者
Wang, Lirong [1 ]
Chen, Jiawen [2 ]
Yuan, Xin [1 ]
Wang, Juan [1 ]
Sun, Lei [1 ]
Jiang, Jue [1 ]
Zhang, Lin [1 ]
Liu, Min [1 ]
Zhou, Qi [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Ultrasound, Affiliated Hosp 2, Xian 710004, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Otolaryngol Head & Neck Surg, Affiliated Hosp 2, Xian 710004, Peoples R China
基金
中国国家自然科学基金;
关键词
Hashimoto's thyroiditis; Papillary thyroid carcinoma; Lymph node metastasis; Predictive model; CHRONIC LYMPHOCYTIC THYROIDITIS; CANCER; ASSOCIATION; COEXISTENCE; RECURRENCE; STAGE;
D O I
10.1186/s12902-021-00923-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Whether Hashimoto's thyroiditis (HT) affects the lymph node metastasis of papillary thyroid carcinoma (PTC) remains uncertain. The diagnostic criteria for HT differed in previous studies. Our study focused on analysing the influence of HT on PTC lymph node metastasis (LNM) with stringent diagnostic criteria for HT. Methods A total of 444 patients diagnosed with PTC from 2019 to 2020 were enrolled and divided into two groups: HT group and non-HT group. Diagnostic criteria of HT were as follows: thyroid peroxidase antibody (+) and postoperative histopathology of Hashimoto's disease. Results There was no significant difference in the LNM rate between HT group and non-HT group. Patients in the HT group had fewer numbers of metastatic LNs and lower metastatic LNs ratio in central region. In the HT group, age < 55 and tumor size >= 10 mm were independent risk factors for central LNM. Conclusion The autoimmune response of HT seems to reduce the central lymph node metastasis of HT PTCs. Age < 55 and tumor size >= 10 mm were independent risk factors of central lymph node metastasis in HT PTCs.
引用
收藏
页数:7
相关论文
共 34 条
[1]   Risk Factors and Outcomes of Postoperative Recurrent Well-Differentiated Thyroid Cancer: A Single Institution's 15-Year Experience [J].
Amin, Shaunak N. ;
Shinn, Justin R. ;
Naguib, Mark M. ;
Netterville, James L. ;
Rohde, Sarah L. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2020, 162 (04) :469-475
[2]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[3]   Thyroid cancer [J].
Cabanillas, Maria E. ;
McFadden, David G. ;
Durante, Cosimo .
LANCET, 2016, 388 (10061) :2783-2795
[4]   Hashimoto thyroiditis: Clinical and diagnostic criteria [J].
Caturegli, P. ;
De Remigis, A. ;
Rose, N. R. .
AUTOIMMUNITY REVIEWS, 2014, 13 (4-5) :391-397
[5]  
Del Rio P, 2008, MINERVA ENDOCRINOL, V33, P1
[6]   Immune and Inflammatory Cells in Thyroid Cancer Microenvironment [J].
Ferrari, Silvia Martina ;
Fallahi, Poupak ;
Galdiero, Maria Rosaria ;
Ruffilli, Ilaria ;
Elia, Giusy ;
Ragusa, Francesca ;
Paparo, Sabrina Rosaria ;
Patrizio, Armando ;
Mazzi, Valeria ;
Varricchi, Gilda ;
Marone, Gianni ;
Antonelli, Alessandro .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (18)
[7]   Thyroid Autoimmunity: Role of Anti-thyroid Antibodies in Thyroid and Extra-Thyroidal Diseases [J].
Froehlich, Eleonore ;
Wahl, Richard .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[8]   Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer [J].
Imam, Shahnawaz ;
Dar, Pervaiz ;
Paparodis, Rodis ;
Almotah, Khalil ;
Al-Khudhair, Ahmed ;
Hasan, Syed Abdul-Moiz ;
Salim, Nancy ;
Jaume, Juan Carlos .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[9]   Predictive Risk-scoring Model For Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma [J].
Jiang, Lie-hao ;
Yin, Ke-xin ;
Wen, Qing-liang ;
Chen, Chao ;
Ge, Ming-hua ;
Tan, Zhuo .
SCIENTIFIC REPORTS, 2020, 10 (01)
[10]   Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer [J].
Jo, Kwanhoon ;
Lim, Dong-Jun .
KOREAN JOURNAL OF INTERNAL MEDICINE, 2018, 33 (06) :1050-1057